Literature DB >> 9783887

Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.

P Stadler1, H J Feldmann, C Creighton, R Kau, M Molls.   

Abstract

PURPOSE: To evaluate the changes in tumor oxygenation during definitive split-course radiochemotherapy in locally advanced head and neck cancer (lymph nodes and primaries).
MATERIALS AND METHODS: Twenty-four patients with locally advanced head and neck cancer were investigated pretherapeutically and during a defined course of radiochemotherapy (RCTh) with a total dose of 70 Gy given in 35 fractions over 9 weeks (2-week break after 30 Gy). In weeks 1 and 6, the patients received chemotherapy (5 FU and mitomycin C) concomitant with irradiation. The oxygen partial pressure measurements were carried out using polarographic needle probes in combination with a microprocessor-controlled device (pO2 histograph/KIMOC). Times of measurements were before therapy, at the end of week 3 (30 Gy), after a 2-week break (30 Gy) and at the end of therapy if measurable lesion was found (70 Gy).
RESULTS: There was a significant reduction in the median pO2 (P < 0.005, n = 18) and an increase in the hypoxic fraction (defined as the percentage of pO2 values of <5 mm Hg) after application of 30 Gy (P < 0.05, n = 18). This effect was partially reversed at the end of the 2-week break. During the break an increase in the median PO2 (P = 0.05, n = 12) and a decrease in the hypoxic fraction could be observed. Towards the end of therapy (70 Gy) a significant decrease (P = 0.02, n = 13) in the median pO2 occurred. Corresponding to this, the hypoxic fraction increased during the last 4 weeks of therapy (P = 0.06, n = 13).
CONCLUSION: Statistically significant changes in oxygenation in locally advanced head and neck cancer were found during a split-course radiochemotherapy. This information was obtained in a homogenous group of patients under well-defined therapeutic conditions. The decrease in the tumor oxygenation status at doses of 30 and 70 Gy are important findings because they are in contrast to the concept of continuous improvement of the oxygenation status during fractionated radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783887     DOI: 10.1016/s0167-8140(98)00032-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Optical tomography with ultrasound localization: initial clinical results and technical challenges.

Authors:  Quing Zhu
Journal:  Technol Cancer Res Treat       Date:  2005-06

Review 2.  Impact of anemia in patients with head and neck cancer treated with radiation therapy.

Authors:  Kenneth Hu; Louis B Harrison
Journal:  Curr Treat Options Oncol       Date:  2005-01

3.  PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.

Authors:  M Busk; L S Mortensen; M Nordsmark; J Overgaard; S Jakobsen; K V Hansen; J Theil; J F Kallehauge; F P D'Andrea; T Steiniche; M R Horsman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-18       Impact factor: 9.236

Review 4.  Blood flow and oxygenation status of human tumors. Clinical investigations.

Authors:  H J Feldmann; M Molls; P Vaupel
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

5.  Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial.

Authors:  Nils H Nicolay; Alexander Rühle; Nicole Wiedenmann; Gabriele Niedermann; Michael Mix; Wolfgang A Weber; Dimos Baltas; Martin Werner; Gian Kayser; Anca-L Grosu
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

6.  The HYP-RT hypoxic tumour radiotherapy algorithm and accelerated repopulation dose per fraction study.

Authors:  W M Harriss-Phillips; E Bezak; E Yeoh
Journal:  Comput Math Methods Med       Date:  2012-06-19       Impact factor: 2.238

7.  Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.

Authors:  Peter Stadler; Kurt Putnik; Thore Kreimeyer; Lisa D Sprague; Oliver Koelbl; Christof Schäfer
Journal:  BMC Cancer       Date:  2006-12-07       Impact factor: 4.430

Review 8.  Hypoxia in Head and Neck Tumors: Characteristics and Development during Therapy.

Authors:  Martin-Immanuel Bittner; Anca-Ligia Grosu
Journal:  Front Oncol       Date:  2013-08-28       Impact factor: 6.244

9.  Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.

Authors:  Steffi U Pigorsch; Jan J Wilkens; Severin Kampfer; Victoria Kehl; Alexander Hapfelmeier; Christian Schläger; Henning Bier; Markus Schwaiger; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2017-03-01       Impact factor: 3.481

10.  Pretreatment apoptosis in carcinoma of the cervix correlates with changes in tumour oxygenation during radiotherapy.

Authors:  M T Sheridan; C M West; R A Cooper; I J Stratford; J P Logue; S E Davidson; R D Hunter
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.